Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.
|See historical ARDS trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 17||Multiple of Ten Bearish||Other||0.00%|
|Dec 17||Inside Day||Range Contraction||0.00%|
|Dec 17||Wide Bands||Range Expansion||0.00%|
|Dec 14||20 DMA Resistance||Bearish||-3.02%|
|Dec 14||Wide Range Bar||Range Expansion||-3.02%|
|Dec 14||Multiple of Ten Bearish||Other||-3.02%|
|Dec 14||Wide Bands||Range Expansion||-3.02%|
|Dec 13||20 DMA Resistance||Bearish||-13.40%|
|Dec 13||1,2,3 Retracement Bearish||Bearish Swing Setup||-13.40%|
|Dec 13||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-13.40%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
- Earnings date: ???
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ARDS news...
|52 Week High||13.85|
|52 Week Low||7.59|
|200-Day Moving Average||0.0|
|50-Day Moving Average||11.7424|
|20-Day Moving Average||10.5695|
|10-Day Moving Average||9.022|
|Average True Range||0.9171|
|Chandelier Exit (Long, 3 ATRs )||9.8687|
|Chandelier Exit (Short, 3 ATRs )||10.3413|
|Upper Bollinger Band||13.9855|
|Lower Bollinger Band||7.1535|
|Percent B (%b)||0.32|
|MACD Signal Line||-0.8107|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||11.40|
|Resistance 3 (R3)||11.52||10.96||11.05|
|Resistance 2 (R2)||10.96||10.43||10.89||10.93|
|Resistance 1 (R1)||10.13||10.10||9.85||10.01||10.82|
|Support 1 (S1)||8.74||9.04||8.46||8.62||7.80|
|Support 2 (S2)||8.18||8.71||8.11||7.69|
|Support 3 (S3)||7.35||8.18||7.57|
|Support 4 (S4)||7.23|